Bio*One Capital manages four funds, namely Singapore BioInnovations Fund (SBI), PharmBioGrowth Fund (PGF), Life Sciences Investments Fund (LSI), and Biomedical Sciences Investments Fund (BMSIF).

Singapore Bio-Innovations (SBI)
The SBI Fund I, established in 1990, had a fund size of S$40 million (approximately US$26 million). Its main objective was to introduce Singapore to the global biotech VC industry by focusing on overseas VC-led investments. This fund was fully realized in 2005.

SBI Fund II was set up in 1998 with a fund size of S$70 million (approximately US$46 million). It is fully invested, and currently has some 15 companies in its portfolio.

PharmBio Growth Fund/Life Sciences Investment Fund (PGF/LSI)
These funds were established in 1998 to co-invest mainly in key projects in Singapore. The combined fund size is S$100 million (approximately US$66 million). The funds are fully invested and currently have 4 companies in its portfolio.

Biomedical Sciences Investment Fund (BMSIF)
Established in 2001, BMSIF’s goal is to make strategic investments leading ultimately to Singapore-based activities. The S$1 billion fund (approximately US$660 million) has to date invested in close to 45 companies.

BMS INC (Innovate ‘N’ Create)
The BMS INC scheme is a $25 million (US$16.5 million) fund created under the BMSIF, dedicated to supporting local biomedical start-ups by providing seed and early stage funding.
Successful ventures will receive investments of between S$250,000 to S$2,000,000 in the form of equity or convertible loans. Here Bio*One Capital takes a hands-on investment approach to growing the company, and works closely with scientists and entrepreneurs to build businesses that will best capitalize on commercially viable research ideas.